ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment for HBV-MN Patients in Chinese: An Open Parallel Controlled Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01152060
Recruitment Status : Unknown
Verified May 2010 by Nanchang University.
Recruitment status was:  Active, not recruiting
First Posted : June 29, 2010
Last Update Posted : June 29, 2010
Sponsor:
Information provided by:
Nanchang University

Brief Summary:
Lamivudine treatment for HBV-DNA negative HBV-GN patients.

Condition or disease
Proteinuria HBVe-antigen

Detailed Description:
lamivudine and predinisone treatment for HBV-DNA negative HBV-GN patients.

Study Type : Observational
Estimated Enrollment : 10 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: an Open Parallel Clinical Trial in HBV-GN Patients
Study Start Date : January 2010
Estimated Primary Completion Date : November 2010
Estimated Study Completion Date : November 2010

Group/Cohort
prednisone
prednisone and anti-virus



Biospecimen Retention:   Samples Without DNA
not available


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
HBV-MN patients with heavy proteinuria in adults; HBsAg or HBeAg positive; HBV-DNA negative
Criteria

Inclusion Criteria:

  • Adult HBV-GN patients with biopsy-proven MN, heavy protinuria, HBsAg or HBeAg positive, HBV-DNA negative

Exclusion Criteria:

  • Primary MN patients, HBV-DNA positive

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01152060


Sponsors and Collaborators
Nanchang University
Investigators
Study Director: Gaosi XU, MD & PhD second affiliated hospital to nanchang university

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: ethics committee of Nanchang University, second affiliated hospital
ClinicalTrials.gov Identifier: NCT01152060     History of Changes
First Posted: June 29, 2010    Key Record Dates
Last Update Posted: June 29, 2010
Last Verified: May 2010

Keywords provided by Nanchang University:
remission of proteinuria
HBVe-antigen

Additional relevant MeSH terms:
Proteinuria
Urination Disorders
Urologic Diseases
Urological Manifestations
Signs and Symptoms
Prednisone
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents